Aptose Biosciences Inc (APTO)

• $0.55

  $0.60

  $0.57
  

  3.51%

  Downside

  Day's Volatility :8.33%

  Upside

  5.0%

  
• $0.57

  $5.10

  $0.57
  

  0.28%

  Downside

  52 Weeks Volatility :88.85%

  Upside

  88.82%

  

Returns

What analysts predicted

Upside of 1887.72%

• DRW Securities, LLC

  3.27%

• Sigma Planning Corp

  1.03%

• Nantahala Capital Management, LLC

  0.49%

• Morgan Stanley - Brokerage Accounts

  0.19%

• Cetera Advisors LLC

  0.12%

• Cetera Investment Advisers

  0.12%

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt